Announcements
- Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
- Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.27 |
---|---|
High | 1.27 |
Low | 1.27 |
Bid | 1.27 |
Offer | 1.31 |
Previous close | 1.30 |
Average volume | 3.31k |
---|---|
Shares outstanding | 114.73m |
Free float | 110.09m |
P/E (TTM) | -- |
Market cap | 159.47m USD |
EPS (TTM) | -0.7801 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:03 BST.
More ▼